ATPW
FOLD

Ashton Thomas Private Wealth’s Amicus Therapeutics FOLD Stock Holding History

Ashton Thomas Private Wealth’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,183
Closed -$11.7K – 1057
2024
Q2 		$11.7K Buy
+1,183
New +$12.1K ﹤0.01% 1292

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Ashton Thomas Private Wealth's FOLD Position: Q3 2024 in Review

Ashton Thomas Private Wealth sold out of Amicus Therapeutics (FOLD) in Q3 2024, closing a stake of 1,183 shares — an estimated $11.7K sold.

Ashton Thomas Private Wealth first reported a position in FOLD in Q2 2024 and held it in 1 quarter. The position peaked at $11.7K in Q2 2024. 293 funds tracked by Wall St. Rank hold FOLD as of Q3 2024.

  • Ashton Thomas Private Wealth reported no remaining Amicus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Ashton Thomas Private Wealth sold 1,183 Amicus Therapeutics shares in Q3 2024, an estimated $11.7K.
  • Ashton Thomas Private Wealth first reported a position in Amicus Therapeutics in Q2 2024 and held it in 1 quarter.
  • Ashton Thomas Private Wealth's Amicus Therapeutics position peaked at $11.7K in Q2 2024.
  • 293 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2024.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2024, filed 5 Nov 2024.